The filing provides audited baseline financials for the acquired Marea business. Monitor the combined company's cash runway given the $225M PIPE and $31M Marea cash at June 30, 2026. Key catalysts are clinical data for MAR001 (severe hypertriglyceridemia) and MAR002 (acromegaly). The Series C preferred stock conversion requires stockholder approval; watch for the proxy vote timeline.
Drugs in focus
LSTA drug pipeline →MAR001/005
● Neutral Named in this 8-K/A- Impact
- Phase
- Phase 2b
- Time to market
- At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
- Next catalyst
- None dated
What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 12 $1.28entry
- T+1 · 9d ago −5.47%α −5.11% · $1.21
- T+5 · 3d ago −28.91%α −23.46% · $0.9100
- T+6 · todayOpen
- T+20 · in 19d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Lisata Therapeutics filed an 8-K/A to provide audited financial statements of Marea Therapeutics (acquired on September 17, 2026) and unaudited pro forma combined financials. The acquisition was structured as a reverse merger: former Marea equity holders own ~59.5% of the combined company on a fully-diluted basis, legacy Lisata holders ~2.4%, and PIPE investors ~38.1%. The combined entity has a $12M market cap with no approved products and substantial operating losses.
Key Facts
- Lisata acquired Marea on September 17, 2026 in a reverse merger; former Marea holders own ~59.5% of combined entity on a fully-diluted basis.
- Concurrent PIPE raised ~$225M gross via Series C non-voting convertible preferred stock.
- Marea's audited combined financials show net losses of $62.6M (2025) and $43.9M (2024); accumulated deficit of $141.3M as of Dec 31, 2025.
- Marea's cash burn was $51.2M (2025) and $44.6M in H1 2026; cash balance fell from $75.3M (Dec 2025) to $31.0M (Jun 2026).
- Marea had a going concern qualification; $65M SAFE was converted to equity pre-merger.
- Pro forma combined net loss was $62.1M for FY2025 and $49.8M for H1 2026.
- Estimated purchase price was $377.8M; $292.9M allocated to IPR&D (MAR001/005, MAR002, MAR003) and $44.9M to goodwill.
- Lisata's market cap is $12M with a 6.4% normal daily move.
Financial Impact
Marea's net losses of $62.6M (FY2025) and $52.2M (H1 2026); pro forma combined net loss of $62.1M (FY2025) and $49.8M (H1 2026). PIPE raised $225M gross. Purchase price $377.8M.
Risk Factors
- Combined entity has no approved products and substantial operating losses; going concern risk persists despite PIPE proceeds.
- Marea's pre-acquisition going concern qualification and rapid cash burn ($44.6M in H1 2026) highlight execution risk.
- Series C preferred stock conversion requires stockholder approval; failure could trigger cash settlement obligations.
- Preliminary purchase price allocation is subject to change; final IPR&D and goodwill values may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001140361-26-043233 |
| Document: ef20085283_ex99-5.htm | 0001140361-26-043233 |
| Document: ef20085283_ex99-4.htm | 0001140361-26-043233 |
| Document: ef20085283_8ka.htm | 0001140361-26-043233 |
Track record
21 reports on LSTA
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
- Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
- Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
- Nov 12, 202610d ago 8-K/A Neutral 4/10 Viewing Entry $1.28 settles Feb 10
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
- Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
- Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
- Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers